<DOC>
	<DOC>NCT00704132</DOC>
	<brief_summary>A clinical study to determine the safety, efficacy and the way sitagliptin works in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control.</brief_summary>
	<brief_title>Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Participant has type 2 diabetes mellitus Males Females who are highly unlikely to become pregnant Participants poorly controlled without taking any, or taking one or two oral antidiabetic medications Participant has a history of type 1 diabetes mellitus or history of ketoacidosis Participant required insulin therapy within the prior 8 weeks Participant is on or has been taking TZDs such as Actos® (pioglitazone) or Avandia® (rosiglitazone) within the prior 12 weeks of the screening visit</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>